Azelaic Acid Therapeutic Cheat Sheet
175831758317583
Azelaic acid is a topical therapeutic agent which is FDA approved to treat papules and pustules of mild to moderate rosacea and mild to moderate acne vulgaris. It was first approved by the FDA in 1995 and since its approval, has been used for many off-label conditions including disorders of hyperpigmentation. Its utility in various conditions can be attributed to its anti-microbial, anti-inflamm …
Azelaic acid is a topical therapeutic agent which is FDA approved to treat papules and pustules of mild to moderate rosacea and mild to moderate acne vulgaris. It was first approved by the FDA in 1995 and since its approval, has been used for many off-label conditions including disorders of hyperpigmentation. Its utility in various conditions can be attributed to its anti-microbial, anti-inflamm … 
A 55-year-old patient from the Caribbean presents with indurated scaly papules and plaques on his trunk, arms, and legs. The rash started six months ago and has progressed rather quickly. Review of system was notable for pruritus and xerosis; patient reported no personal history of skin diseases, including psoriasis and atopic dermatitis. Several 4-mm punch biopsies were performed. Based on th … 
Dermatologic side effects are among the most frequent unexpected side effects of cancer treatments.1,2 Targeted therapies are associated with a lower incidence of systemic adverse events, but a higher incidence of dermatological AEs - including acneiform rash and pruritus.3
Skin toxicities can have a dramatic negative impact on QOL and overall success of treatment therapies.3
Skin toxicities oft … 
As dermatologists, pruritus (or itch) is one of the most frequent symptoms that we encounter. The broad spectrum of itch severity in patients with various dermatologic conditions suggests a need for a host of “tools” or medications that dermatologists should have in their toolbox. In this publication, we continue our Therapeutic Cheat Sheet series by highlighting the uses of Doxepin in dermato … 
During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.
CASE 1
51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA … 